Having had setbacks with torcetrapib and Exubera, and with generic competition to Norvasc and Lipitor, Pfizer is putting more emphasis into animal drugs.
Pfizer: Going to the dogs
ADVERTISEMENT
ADVERTISEMENT
More in Uncategorized
Past Week
-
How the CDC’s opioid rules created a crisis for chronic pain patients
-
How to build a culture where physicians feel valued [PODCAST]
-
Why vaccine access still fails America’s most vulnerable groups
-
Medical school admissions are racing toward an AI-driven disaster
-
The silent crisis hurting pain patients and their doctors
-
From the other side of the table: a plea for empathy
-
Past 6 Months
-
How trade wars could destroy the U.S. health care system
-
Cutting opioid use in half: a hospital’s pain management breakthrough
-
How hospitals are quietly taking control of physicians
-
The hidden bias young female physicians face every day
-
How the system hunts physicians who refuse to kneel
-
How to advocate for your transgender child’s health care
-
Recent Posts
-
A surgeon’s startling ketamine experience [PODCAST]
-
How doctors can thrive despite declining reimbursements
-
How DrKoop.com rose and fell: the untold story behind the Surgeon General’s startup
-
Why prescribing medicine to kids scares even experienced doctors
-
When empathy becomes “toxic”
-
Leading with care: a new approach to health care leadership for well-being [PODCAST]
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
